Marcus Ballinger

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 juli 2025

Efficacy and safety of eerstelijns maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-...

Lancet (London, England) · 14 juni 2025

Atezolizumab in High-Risk Locally Gevorderd Squamous Cell Carcinoma of the Head and Neck: A Gerandomiseerde Klinische...

JAMA · 13 mei 2025

Atezolizumab plus cabozantinib versus docetaxel bij gemetastaseerd NSCLC: CONTACT-01 fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 juli 2024

Atezolizumab versus docetaxel bij NSCLC: IMpower210 definitief

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021-01

Atezolizumab plus carboplatine-nab-paclitaxel bij plaveiselcel-NSCLC: IMpower131 fase III

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2020-08

Neoadjuvante nivolumab-ipilimumab bij gemetastaseerd melanoom: biologische correlaten

Clinical cancer research : an official journal of the American Association for Cancer Research · 15 oktober 2019

Atezolizumab doorbehandelen na progressie bij NSCLC: OAK analyse

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018-12

Geactualiseerde OAK-analyse: atezolizumab versus docetaxel bij gevorderd NSCLC

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018-08

Atezolizumab versus docetaxel bij eerder behandeld NSCLC: OAK fase III-studie

Lancet (London, England) · 21 januari 2017

Atezolizumab versus docetaxel bij eerder behandeld NSCLC: POPLAR fase II

Lancet (London, England) · 30 april 2016

Publicaties op Oncologisch.com